Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Johnson and Johnson
Dow
Express Scripts
Harvard Business School

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ulimorelin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Ulimorelin: Patents, clinical trial progress, indications

Ulimorelin is an investigational drug.

There have been 7 clinical trials for Ulimorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Gastrointestinal Diseases, Digestive System Diseases, and Liver Diseases. The leading clinical trial sponsors are Norgine, Tranzyme, Inc., and Lyric Pharmaceuticals.

There are nine US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for Ulimorelin
TitleSponsorPhase
Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE TrialLyric PharmaceuticalsPhase 2
A Study to Assess Ulimorelin in Healthy SubjectsLyric PharmaceuticalsPhase 1
A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel ResectionNorginePhase 3

See all Ulimorelin clinical trials

Clinical Trial Summary for Ulimorelin

Top disease conditions for Ulimorelin
Top clinical trial sponsors for Ulimorelin

See all Ulimorelin clinical trials

US Patents for Ulimorelin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ulimorelin   Start Trial Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists Tranzyme Pharma, Inc. (CA)   Start Trial
Ulimorelin   Start Trial Macrocyclic modulators of the ghrelin receptor Tranzyme Pharma, Inc. (Quebec, CA)   Start Trial
Ulimorelin   Start Trial Methods of using macrocyclic modulators of the ghrelin receptor Tranzyme Pharma Inc. (Quebec, CA)   Start Trial
Ulimorelin   Start Trial Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders Tranzyme Pharma Inc. (CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ulimorelin

Drugname Country Document Number Estimated Expiration Related US Patent
Ulimorelin Austria 490264 2023-07-31   Start Trial
Ulimorelin Australia 2004261329 2023-07-31   Start Trial
Ulimorelin Canada 2533818 2023-07-31   Start Trial
Ulimorelin Cyprus 1111901 2023-07-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Express Scripts
Dow
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.